TABLE IV.

Univariate and multivariate analyses of young chemotherapy (CTx)–treated breast cancer survivors reporting regular menses at the time of posttreatment anti-Müllerian hormone testing

Predictor	Univariate			Multivariate
	β	95% CI	p Value	β	95% CI	p Value
Attained age	−0.042	−0.083 to 0.001	0.042	−0.057	−0.094 to −0.020	0.002
Irregular cycles or amenorrhea during CTxa	−0.781	−1.392 to −0.169	0.012	−0.983	−1.548 to −0.417	<0.001
Age at diagnosis	−0.050	−0.097 to −0.002	0.041	—	—
Body mass index	0.006	−0.033 to 0.046	0.749	—	—
Cyclophosphamide use (g/m2)	−0.045	−0.16 to 0.079	0.477	—	—
Irregular cycles before CTxa	0.607	−0.361 to 1.58	0.219	—	—
Irregular cycles after CTxa	−0.404	−0.904 to −0.096	0.114	—	—
Tamoxifen exposure	0.256	−0.268 to 0.780	0.338	—	—
Trastuzumab exposure	0.592	0.067 to 1.116	0.027	—	—
Years after CTx	−0.015	−0.086 to 0.056	0.67	—	—

^aReferenced against regular menstrual cycles.

CI = confidence interval.